SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001214659-24-001777
Filing Date
2024-02-02
Accepted
2024-02-02 16:30:35
Documents
17
Period of Report
2024-02-02
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.02: Unregistered Sales of Equity Securities
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 o212438k.htm   iXBRL 8-K 44181
2 EXHIBIT 3.1 ex3_1.htm EX-3.1 89148
3 EXHIBIT 10.1 ex10_1.htm EX-10.1 258812
4 EXHIBIT 10.2 ex10_2.htm EX-10.2 74548
  Complete submission text file 0001214659-24-001777.txt   758705

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE alzn-20240202.xsd EX-101.SCH 2991
6 XBRL LABEL FILE alzn-20240202_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE alzn-20240202_pre.xml EX-101.PRE 22343
18 EXTRACTED XBRL INSTANCE DOCUMENT o212438k_htm.xml XML 3953
Mailing Address 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326
Business Address 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326 844-722-6333
Alzamend Neuro, Inc. (Filer) CIK: 0001677077 (see all company filings)

IRS No.: 811822909 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 8-K | Act: 34 | File No.: 001-40483 | Film No.: 24591968
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)